Latest Breaking News On - Cadila pharmaceuticals ltd - Page 20 : comparemela.com

Worldwide Anterior Uveitis Treatment Industry to 2026 – Key Motivators, Restraints and Opportunities – ResearchAndMarkets com

ResearchAndMarkets.com’s offering. The global anterior uveitis treatment market is projected to witness considerable growth during the forecast period. The major factors contributing to the growth of the market include the increasing prevalence of anterior uveitis due to the rising incidence of optical infections. In addition, the rising medical tourism and an expected approval for products under clinical trial and development is further estimated to propel the market growth during the forecast period. The anterior uveitis treatment market is classified on the basis of therapeutics into corticosteroids, anti-inflammatory agents, cycloplegics, antimetabolites, biologics, and others. Among these range of therapeutics, corticosteroids is estimated to project a considerable CAGR during the forecast period. The corticosteroids are predominantly used as a first treatment option for anterior uveitis, owing to which, the demand is high for corticosteroids across the globe.

United statesUnited kingdomLaura woodSanten pharmaceutical co ltdAlimera sciences incCadila pharmaceuticals ltdCompany share analysisClearside biomedical incPfizer incAldeyra therapeutics incAbbvie incKey company analysisBausch health companies incOffice hours callPrometheus laboratories incCompany profiles

Intranasal Drug Delivery Devices Market Size, Share, Industry Analysis and Global Forecast to 2027 | GlaxoSmithKline PLC AstraZeneca PLC, Pfizer Inc, OptiNose Inc, etc

Intranasal Drug Delivery Devices Market Size, Share, Industry Analysis and Global Forecast to 2027 | GlaxoSmithKline PLC AstraZeneca PLC, Pfizer Inc, OptiNose Inc, etc
texasguardian.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from texasguardian.com Daily Mail and Mail on Sunday newspapers.

United statesJohn watsonAsia pacificPharma ltdBf ascher company incCadila pharmaceuticals ltdPromius pharmaDouglas pharmaceuticals ltdCompany profilesOptinose incResearch newswirePfizer incSee campaignPendopharm incHead of business developmentGlobal intranasal drug delivery devices market

Altus Formulation Inc : Cadila Pharmaceuticals and Altus Formulation Announce Successful Clinical Studies with TramaFlex Breakable Extended-Release Tablets

Altus Formulation Inc.: Cadila Pharmaceuticals and Altus Formulation Announce Successful Clinical Studies with TramaFlex Breakable Extended-Release Tablets tm Modified Release Technology Platform: New Safer to Use Value Added Tablets AHMEDABAD, INDIA and LAVAL, QC / ACCESSWIRE / January 27, 2021 / Cadila Pharmaceuticals Limited ( Cadila ) and Altus ) today announced the successful completion of human clinical studies with TramaFlex TM breakable extended-release (ER) tablets, a novel value-added once-daily formulation of tramadol hydrochloride for the improved treatment of patients with moderate to moderately severe pain. Developed by Altus using proprietary AmyloFlex TM technology, human bio-equivalence studies conducted by Cadila demonstrated TramaFlex ER tablets are bio-equivalent to 24hr ER products available commercially in North America, Europe, and Asia. Unlike marketed brands that can rapidly release their entire contents if damaged, with potentially life-threatenin

United statesM robert bechardKostenloser wertpapierhandelDamon smithCadila pharmaceuticals limitedCorporate developmentTechnology platformAltus formulation incCadila pharmaceuticals ltdCadila pharmaceuticalsSuccessful validationModified release technology platformNew saferUse value addedAltus formulationNorth america

Cadila Pharmaceuticals and Altus Formulation Announce Successful Clinical Studies with TramaFlex Breakable Extended-Release Tablets

Cadila Pharmaceuticals and Altus Formulation Announce Successful Clinical Studies with TramaFlex Breakable Extended-Release Tablets
theusnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theusnews.com Daily Mail and Mail on Sunday newspapers.

United statesM robert bechardDamon smithCadila pharmaceuticals limitedCorporate developmentTechnology platformAltus formulation incCadila pharmaceuticals ltdCadila pharmaceuticalsSuccessful validationRelease technology platformNew saferUse value addedAltus formulationNorth americaRajiv modi

North America Nasal Delivery Devices Market to Clock CAGR of 6 8% during 2020

North America Nasal Delivery Devices Market to Clock CAGR of 6 8% during 2020
sandiegosun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sandiegosun.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesMedia telecommunicationsSemiconductor electronicsCadila pharmaceuticals ltdMerck co incAerospace defenseResearch newswirePfizer incResearch findings conclusionAmerica nasal delivery devices market researchCompany segmentTechnology sources analysisMarket researchSee campaignNeurelis inc